WallStreetZenWallStreetZen

NASDAQ: PCVX
Vaxcyte Inc Stock Forecast, Predictions & Price Target

Analyst price target for PCVX

Based on 3 analysts offering 12 month price targets for Vaxcyte Inc.
Min Forecast
$58.00-24.55%
Avg Forecast
$69.00-10.24%
Max Forecast
$80.00+4.07%

Should I buy or sell PCVX stock?

Based on 3 analysts offering ratings for Vaxcyte Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PCVX stock forecasts and price targets.

PCVX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-02Find Out Why
lockedlocked$00.00+00.00%2023-12-07
lockedlocked$00.00+00.00%2023-11-07

1 of 1

Forecast return on equity

Is PCVX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.62%

Forecast return on assets

Is PCVX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

PCVX revenue forecast

What is PCVX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$278.6M
Avg 2 year Forecast
$101.6M
Avg 3 year Forecast
$376.0M

PCVX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PCVX$76.87$69.00-10.24%Strong Buy
CERE$40.88$44.13+7.94%Hold
CYTK$78.02$83.36+6.85%Strong Buy
CRSP$83.99$81.20-3.32%Buy
IONS$45.36$54.50+20.15%Buy

Vaxcyte Stock Forecast FAQ

Is Vaxcyte Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PCVX) stock is to Strong Buy PCVX stock.

Out of 3 analysts, 2 (66.67%) are recommending PCVX as a Strong Buy, 1 (33.33%) are recommending PCVX as a Buy, 0 (0%) are recommending PCVX as a Hold, 0 (0%) are recommending PCVX as a Sell, and 0 (0%) are recommending PCVX as a Strong Sell.

If you're new to stock investing, here's how to buy Vaxcyte stock.

What is PCVX's revenue growth forecast for 2026-2028?

(NASDAQ: PCVX) Vaxcyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 52.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.

Vaxcyte's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast PCVX's revenue for 2026 to be $26,509,879,047, with the lowest PCVX revenue forecast at $26,509,879,047, and the highest PCVX revenue forecast at $26,509,879,047. On average, 2 Wall Street analysts forecast PCVX's revenue for 2027 to be $9,662,879,459, with the lowest PCVX revenue forecast at $7,583,766,547, and the highest PCVX revenue forecast at $11,741,992,371.

In 2028, PCVX is forecast to generate $35,777,869,784 in revenue, with the lowest revenue forecast at $14,292,117,132 and the highest revenue forecast at $57,263,622,436.

What is PCVX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PCVX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is PCVX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PCVX price target, the average PCVX price target is $69.00, with the highest PCVX stock price forecast at $80.00 and the lowest PCVX stock price forecast at $58.00.

On average, Wall Street analysts predict that Vaxcyte's share price could fall to $69.00 by Jan 2, 2025. The average Vaxcyte stock price prediction forecasts a potential downside of 10.24% from the current PCVX share price of $76.87.

What is PCVX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PCVX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.